

PBMC Humanized Tumor Models for TCE Evaluation




2025.09

T-cell engagers (TCE)

What is T-cell engagers (TCE)?

- Bispecific antibodies (tumor antigen x CD3)
- Form immune synapse between T cells and tumor cells
- MHC-independent recognition
- Strong cytotoxic activity at low antigen levels



Anticancer Res. 2021 Mar;41(3):1123-1141.



Drug	Target	Indication
Blinatumomab (Blincyto)	CD19 x CD3	Relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Mosunetuzumab (Lunsumio)	CD20 x CD3	Relapsed/refractory follicular lymphoma.
Epcoritamab (Epkinly / Tepkinly)	CD20 x CD3	Relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Teclistamab (Tecvayli)	BCMA x CD3	Relapsed/refractory multiple myeloma.
Glofitamab (Columvi)	CD20 x CD3	Relapsed/refractory large B-cell lymphoma.
Tarlatamab (Imdelltra)	DLL3 x CD3	Extensive-stage small-cell lung cancer (ES-SCLC).
Linvoseltamab (Lynozytic)	BCMA x CD3	Relapsed/refractory multiple myeloma.

PBMC humanized tumor models


What is PBMC humanized tumor model?

- T cell focused studies, quick and flexible
- 1~2 weeks for re-constitution
- 2~4 weeks of dosing & observation window
- 3 re-constitution methods for different study purposes
- Allowing for studies on 1900+ PDX/CDX models

Successful human lymphocyte engraftment



Well-validated Models in House



Well-validated Targets

Systemic (IP or IV) injection of hPBMC

- Clinical relevant
- IND and translational research


Co-inoculation of hPBMC with tumor cells

- Straight-forward E/T interaction
- MoA and lead screening

Showcase of TCE evaluation in PBMC humanized tumor models


DLL3 x CD3

Cancer type	Tumor model
Lung cancer	SHP77
	SHP77-luc
	NCI-H524
	NCI-H82
	NCI-H69




CD19 x CD3

Cancer type	Tumor model
Lymphoma	Raji
	Ramos
	Ibrutinib-R-LY
	LY-24-0054
Leukemia	LY-24-0177
	NALM-6-luc




EpCAM x CD3

Cancer type	Tumor model
Lung cancer	NCI-H1650
Bladder cancer	RT112/84



PSMA x CD3

Cancer type	Tumor model
Prostate cancer	LNCap FGC
	22RV1





OUR COMMITMENT

Improving Health. Making a Difference.

For questions and requests, please email to Pharmacology-BD-Translation@wuxiapptec.com



<https://onco.wuxiapptec.com>